Publications by authors named "Mark Swingle"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

56

Total Likes

2

Extended Reach

3,859

Social Features

2
U
Using nanobodies for breast cancer treatment.
Sapthala P L Galappaththi, Mark R Swingle

J Pharmacol Exp Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The phosphatase activity of the PPP2R5D-PP2A holoenzyme modulates liprin-α1 liquid-liquid phase separation.
Abigail Mayer, Rita Derua, Elijah Spahn, Iris Verbinnen, Yang Zhang, Mark R Swingle

J Biol Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of liprin-α1 phosphorylation in its liquid-liquid phase separation: regulation by PPP2R5D/PP2A holoenzyme.
Abigail Mayer, Rita Derua, Elijah Spahn, Iris Verbinnen, Yang Zhang, Mark R Swingle

bioRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B56δ long-disordered arms form a dynamic PP2A regulation interface coupled with global allostery and Jordan's syndrome mutations.
Cheng-Guo Wu, Vijaya K Balakrishnan, Ronald A Merrill, Pankaj S Parihar, Kirill Konovolov, Mark R Swingle

Proc Natl Acad Sci U S A· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascades.
Kali A Smolen, Cinta M Papke, Mark R Swingle, Alla Musiyenko, Chenchen Li

J Biol Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended regulation interface coupled to the allosteric network and disease mutations in the PP2A-B56δ holoenzyme.
Cheng-Guo Wu, Vijaya K Balakrishnan, Pankaj S Parihar, Kirill Konovolov, Yu-Chia Chen, Mark R Swingle

bioRxiv· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A disorder-related variant (E420K) of a PP2A-regulatory subunit (PPP2R5D) causes constitutively active AKT-mTOR signaling and uncoordinated cell growth.
Cinta M Papke, Kali A Smolen, Mark R Swingle, Lauren Cressey, Richard A Heng

J Biol Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
Leia C Shuhaibar, Nabil Kaci, Jeremy R Egbert, Thibault Horville, Léa Loisay, Mark R Swingle

JCI Insight· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of Serine/Threonine Protein Phosphatases: Biochemical and Structural Studies Provide Insight for Further Development.
Mark R Swingle, Richard E Honkanen

Curr Med Chem· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Synthetic 3-ketosteroid Δ-dehydrogenase for the Generation of a Novel Catabolic Pathway Enabling Cholesterol Degradation in Human Cells.
Brandon M D'Arcy, Mark R Swingle, Lindsay Schambeau, Lewis Pannell, Aishwarya Prakash

Sci Rep· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C.
Brandon M D'Arcy, Mark R Swingle, Cinta M Papke, Kevin A Abney, Erin S Bouska

Mol Cancer Ther· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP1:Tautomycetin Complex Reveals a Path toward the Development of PP1-Specific Inhibitors.
Meng S Choy, Mark Swingle, Brandon D'Arcy, Kevin Abney, Scott F Rusin

J Am Chem Soc· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Ultra-High-Throughput Screen for Catalytic Inhibitors of Serine/Threonine Protein Phosphatases Types 1 and 5 (PP1C and PP5C).
Mark Swingle, Claude-Henry Volmar, S Adrian Saldanha, Peter Chase, Christina Eberhart

SLAS Discov· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.
Debasish Chattopadhyay, Mark R Swingle, Edward A Salter, Eric Wood, Brandon D'Arcy

Biochem Pharmacol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).
Mark R Swingle, Richard E Honkanen

Assay Drug Dev Technol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity.
Xiulan Yang, Yanping Liu, Xi-Ming Yang, Fangdi Hu, Lin Cui, Mark R Swingle

Basic Res Cardiol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total synthesis and evaluation of phostriecin and key structural analogues.
Christopher P Burke, Mark R Swingle, Richard E Honkanen, Dale L Boger

J Org Chem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Mark R Swingle, Lauren Amable, Brian G Lawhorn, Suzanne B Buck, Christopher P Burke

J Pharmacol Exp Ther· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer.
Teresa Golden, Mark Swingle, Richard E Honkanen

Cancer Metastasis Rev· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High yield expression of serine/threonine protein phosphatase type 5, and a fluorescent assay suitable for use in the detection of catalytic inhibitors.
Li Ni, Mark S Swingle, Austin C Bourgeois, Richard E Honkanen

Assay Drug Dev Technol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse.
Mark Swingle, Li Ni, Richard E Honkanen

Methods Mol Biol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
Brian G Lawhorn, Sobhana B Boga, Scott E Wolkenberg, David A Colby, Carla-Maria Gauss, Mark R Swingle

J Am Chem Soc· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natal homing in juvenile loggerhead turtles (Caretta caretta).
Brian W Bowen, Anna L Bass, Shaio-Mei Chow, Meredith Bostrom, Karen A Bjorndal, Mark Swingle

Mol Ecol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5.
Mark R Swingle, Richard E Honkanen, Ewa M Ciszak

J Biol Chem· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis